Xeniler

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Xeniler

Quick Facts

Property Description
Active ingredient Cetirizine Hydrochloride
Form Tablet, Oral solution
Pharmacological class Second-Generation Antihistamine
General purpose Symptomatic relief of allergic manifestations
Origin Synthetic compound

What is Xeniler and What is it Made Of?

Xeniler is a synthetic pharmaceutical preparation intended for systemic use, containing the single active ingredient, Cetirizine Hydrochloride. This medicine is available in tablet form or as an oral solution for oral administration. Cetirizine Hydrochloride is a specific chemical entity, identifying Xeniler as a synthetically derived, single-entity pharmaceutical compound rather than a natural or combination product. This compound is indicated for targeted allergy management.

Xeniler’s Pharmacological Class and Purpose

Xeniler belongs to the pharmacological class of second-generation antihistamines, which is defined by its selective action against the allergic response mediator, histamine. Its active ingredient acts as a selective Histamine H1 Receptor Antagonist. The mechanism is characterized by peripheral selectivity, a feature that focuses the drug's activity on peripheral body tissues where allergic symptoms manifest.

The general purpose of Xeniler is to provide symptomatic relief by mitigating the physical manifestations of allergic reactions, such as hay fever symptoms. This action works to control the inflammatory response to allergens, assisting in the management of patient comfort and physical function.

Regulatory References

  1. National Library of Medicine (MedlinePlus)

What side effects are possible with Xeniler?

Possible side effects and safety information

The safety profile of Xeniler (Cetirizine Hydrochloride) is officially documented across several categories of adverse reactions, based on regulatory reports from health authorities.

Frequency-Classified Adverse Reactions

Adverse events are classified according to frequency observed in clinical trials and post-marketing experience. Common reactions (affecting up to 1 in 10 people) typically include effects related to the central nervous system and digestive tract, such as somnolence (drowsiness), headache, fatigue, and dry mouth.

Uncommon reactions may include agitation or pruritus (itching). Rare reports encompass events like tachycardia (rapid heart rate), hypersensitivity reactions, and temporary abnormalities in liver function tests. Very Rare events, affecting less than 1 in 10,000 people, include anaphylactic shock and oculogyric crisis. Post-marketing surveillance has also documented events, such as urinary retention, whose frequency cannot be estimated (Not Known).

System-Organ Classes and Serious Reactions

Adverse reactions are formally grouped into system-organ classes, including Nervous System Disorders, Gastrointestinal Disorders, and Skin and Subcutaneous Tissue Disorders. While rare, the official labeling documents serious adverse reactions, including anaphylactic shock and angioedema (swelling beneath the skin), which represent severe hypersensitivity.

Population-Specific Safety Constraints

The medicine is contraindicated for individuals with severe renal failure (creatinine clearance less than 10 mL/min). The regulatory documents advise caution and dose adjustment for patients with lesser degrees of renal and hepatic impairment, as the drug is primarily eliminated by the kidneys. Furthermore, caution is recommended in patients with a predisposition to urinary retention due to documented reports of this event.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documents classify Xeniler (Cetirizine Hydrochloride) overdose based on documented physiological manifestations, primarily involving the Central Nervous System (CNS). Common manifestations reported following the ingestion of elevated doses include pronounced drowsiness (somnolence), fatigue, headache, confusion, dizziness, and stupor. Regulatory reports for overdose in pediatric patients specifically note an initial presentation of restlessness and irritability followed by drowsiness. Other reported effects in the overdose context may include diarrhoea and urinary retention. Severe outcomes, such as seizures and coma, have been reported in rare, extreme cases.

Emergency Actions Required

Regulatory labeling strictly mandates that in the event of suspected overdose, an individual must get medical help or contact a Poison Control Center right away. It is required to call emergency services immediately if the affected person has collapsed, experienced a seizure, or has trouble breathing.

Management and Antidote

The official prescribing information confirms that there is no known specific antidote for Cetirizine. Consequently, overdose management is defined as symptomatic and supportive treatment. Furthermore, official regulatory information specifies that the drug is not effectively removed by dialysis.

Therapeutic Uses of Xeniler

What Xeniler Treats: Main Uses and Benefits

Xeniler is a pharmacological treatment primarily utilized for the management of allergic conditions. It belongs to a class of medications known as antihistamines, which work by modulating the body's immune response to environmental triggers.

Primary Indications

The medication is frequently used to address symptoms associated with both seasonal and year-round allergies. These conditions typically manifest in the following ways:

  • Allergic Rhinitis: This includes the relief of sneezing, nasal congestion, and an itchy or runny nose. It is effective for symptoms triggered by pollen, dust mites, or pet dander.
  • Allergic Conjunctivitis: The treatment helps manage ocular symptoms such as red, itchy, and watery eyes.
  • Chronic Urticaria: Xeniler is indicated for the treatment of chronic hives, helping to reduce the appearance of skin wheals and alleviate associated itching.

Therapeutic Benefits

The primary objective of treatment with Xeniler is to improve the patient's quality of life by reducing the physiological impact of allergens. The benefits of this therapy include:

  • Symptom Reduction: By blocking histamine receptors, the medication prevents the inflammatory cascade that leads to common allergic discomforts.
  • Improved Daily Functioning: Reducing persistent symptoms such as sneezing or skin irritation can help minimize disruptions to daily activities and sleep patterns.
  • Non-Sedating Profile: As a second-generation antihistamine, Xeniler is designed to provide relief with a lower likelihood of causing drowsiness compared to older antihistamine generations, allowing patients to maintain their usual level of alertness.

Regulatory References

  1. NIH DailyMed drug label information

Eligibility and Restrictions for Use

Who Can and Cannot Use Xeniler?

Xeniler (Cetirizine) eligibility is determined by specific regulatory criteria concerning age, allergy status, and organ function. The regulatory label defines three primary groups: contraindicated, approved, and restricted populations.

Contraindicated Populations

Use of Xeniler is absolutely contraindicated for patients who have a known hypersensitivity or allergic reaction to the active ingredient, Cetirizine Hydrochloride, or its metabolite, Hydroxyzine. It is also prohibited for patients with End-Stage Renal Disease or severe renal impairment (Creatinine Clearance < 10 mL/min). Tablet formulations are contraindicated in individuals with certain rare hereditary metabolic disorders, such as galactose intolerance.

Approved and Restricted Use

Adults and adolescents are approved for use. The medicine is approved for children aged 6 months and older (via oral solution), but the tablet formulation is generally not recommended for children under six years of age. Use is not recommended for women who are pregnant or breastfeeding as the substance is excreted in human breast milk. Patients with moderate renal or hepatic impairment are eligible but require strict, conditional use, including mandatory regulatory dose adjustment. Caution is also necessary for patients with a predisposition to urinary retention or those at risk of convulsions.

What should I know about interactions with other medicines?

The official regulatory profile for Xeniler (Cetirizine Hydrochloride) details interaction patterns primarily categorized as pharmacodynamic additive effects and pharmacokinetic clearance modifications. The profile establishes specific constraints based on official findings.

Official Interaction Statements and Constraints

Interaction Category Interacting Substance Regulatory Description of Outcome
Pharmacodynamic Alcohol and CNS Depressants Concurrent use should be avoided due to an additive reduction in alertness and increased impairment of performance.
Pharmacokinetic Theophylline (400 mg daily) Results in a 16% decrease in Xeniler clearance. Theophylline's own disposition is unaffected by this combination.

A key restriction noted in regulatory documents is the necessity to avoid concurrent use with substances classified as Central Nervous System (CNS) depressants, including alcohol. This constraint addresses the official finding of potential additive effects on CNS performance.

In specific populations, the pharmacokinetics of Xeniler are officially altered. Patients with chronic liver diseases demonstrate a significant 50% increase in the drug's half-life and a 40% decrease in its clearance compared to healthy subjects. Regarding administration conditions, food is documented to decrease the rate of absorption of Xeniler, though the total amount of drug absorbed is not reduced. Finally, no clinically significant interactions were observed with common co-administered medicines such as Pseudoephedrine, Erythromycin, or Azithromycin.

Mechanism of Action

The mechanism of Xeniler centers on its role as a selective antagonist of the peripheral Histamine mathrmH1 Receptors (mathrmH1 R). By tightly binding to and inactivating these receptors on endothelial cells and sensory nerves, the molecule prevents histamine from activating its usual signaling cascade. This action directly results in the stabilization of capillary walls, restricting the leakage of fluid into surrounding tissues, and inhibiting nerve stimulation, thereby modulating signal transduction in targeted pathways. Beyond receptor blockade, the mechanism of action extends to modulating the underlying inflammatory process. Xeniler actively restricts the chemotaxis (migration) of inflammatory cells, particularly eosinophils, to reactive sites and suppresses the activation of pro-inflammatory molecular pathways like NF-kappaB. This effect engages mechanisms that regulate the cellular cascade of inflammation, influencing the progression of the cellular cascade of inflammation, resulting in changes to mediator activity within targeted pathways.

A key feature of the drug’s mechanism is its constrained activity outside the central nervous system (CNS). Due to its zwitterionic structure and recognition by the P-glycoprotein efflux pump, the molecule is actively excluded from the brain. This peripheral selectivity focuses the drug's primary action on peripheral tissues, resulting in limited engagement with central neurological targets, and low occupation of central mathrmH1 R.

Dosage and Administration Information

How to use Xeniler

Xeniler (Cetirizine Hydrochloride) is utilized for systemic administration, following specific use patterns. The medication is delivered via the oral route (tablet or solution) for standard use. An intravenous (IV) formulation is also an approved route for use in settings requiring specific acute administration protocols.

Dosing and Frequency

The standard oral dosing regimen for adults and adolescents (12 years of age or older) is 10 mg taken once daily. The maximum daily dose for these groups is 10 mg in a 24-hour period. The IV dose is administered once every 24 hours, consistent with the daily frequency pattern.

Administration Protocol

Oral Xeniler may be administered with or without food, as administration is independent of meal timing. The tablet form must be swallowed whole with a liquid. When administering the oral solution, an accurate dosing syringe or cup is required for precise volume measurement. For the IV route, the injection is required to be delivered as a slow intravenous push over a period of one to two minutes.

Population-Specific Use

A dose reduction is a consideration for patients with impaired renal function, where a lower dosage is utilized to manage systemic exposure. For older adults, while an automatic reduction is not mandated if kidney function is normal, initiating therapy at the 5 mg dose may be appropriate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Xeniler


Evidence for Use in Seasonal and Perennial Allergic Rhinitis

Research exploring Xeniler's use in conditions characterized by allergic rhinitis is founded primarily on Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies examined how symptoms change over time across different age groups. The outcomes monitored often related to patient-reported outcomes describing perceived discomfort, tracking changes in sneezing, runny nose, and itching.

Studies were designed to measure changes in symptom scores over short time intervals, typically lasting just a few weeks. Populations studied included adults, adolescents, and children as young as two years old. While the available data provide insight into short-term changes, follow-up durations were limited for many efficacy trials, meaning that the evidence status of long-term outcomes is not fully established based on these specific studies alone.


Evidence for Use in Chronic Urticaria (Hives)

Xeniler was studied for its application in chronic urticaria (hives), one of the conditions characterized by fluctuating manifestations. This research includes RCTs and observational data. The study outcomes examined were outcomes linked to inflammatory states, such as the severity of weals and pruritus (itching). The research has also explored its use in patients whose symptoms were less responsive to the standard dose, though evidence quality varies across these specific studies.

For standard-dose use, the evidence base is relatively consistent; however, sample sizes were modest in some studies investigating different patient subgroups. Additionally, there is limited information for long-term outcomes regarding the drug's effect on the underlying condition, as most trials focus on tracking short-term symptom changes.


What Remains Uncertain and Research Gaps

Limited information for long-term outcomes is a recognized gap, particularly regarding the effects of continuous use over many years. Findings were mixed in the smaller studies that examined patients whose symptoms were less responsive to the standard dose, indicating that comparative evidence is lacking to definitively guide approaches for these complex cases. Overall, the research provides context but not individual predictions, and the results apply only to the populations and specific conditions under which they were conducted.

Frequently Asked Questions (FAQ)

Common questions about Xeniler (FAQ)


Q: Is Xeniler the same type of medicine as [similar common drug name]?

Xeniler is officially classified as a second-generation antihistamine. This category of medicine is known for being highly selective, primarily targeting Histamine H1 receptors in the body's peripheral tissues. Its peripheral focus is a feature that is described as differentiating it from some older compounds, based on official product information.


Q: Can Xeniler interact with herbal supplements like St. John's Wort?

Official regulatory documents specifically warn against the use of Xeniler with alcohol, CNS depressants, and Theophylline due to the risk of additive side effects. However, there are no specific warnings or formal findings regarding interactions with herbal supplements such as St. John's Wort listed in the core regulatory drug information.


Q: How long is Xeniler usually prescribed for?

Studies supporting the primary uses of Xeniler typically tracked symptom relief over short time intervals, often a few weeks. The regulatory view acknowledges that long-term outcomes are not fully established from these specific studies alone. Separately, a safety update noted that stopping the medicine after a prolonged period of long-term daily use may rarely result in severe itching.


Q: Is there a generic version of Xeniler available yet?

Yes, the active ingredient in Xeniler, Cetirizine Hydrochloride, is widely available. Regulatory agencies have approved generic forms from many manufacturers, indicating that the initial key patents for the oral formulation have expired.


Q: Does Xeniler require any special monitoring or regular blood tests?

Official labeling documents do not mandate routine blood tests for standard use in the general population. However, because the medicine is cleared by the kidneys and liver, the labeling advises caution and dose adjustment for people who have existing renal or hepatic impairment. Rare reports of temporary abnormalities in liver function tests have been noted in the safety profile.


Q: What is the purpose of the black box warning on Xeniler?

The official labeling for Xeniler does not include a Black Box Warning (the FDA's strongest warning). However, a regulatory safety update was issued regarding a potential rare side effect of severe itching when the medicine is stopped suddenly after long-term daily use.


Q: Can Xeniler interact with birth control pills?

Official regulatory resources and drug interaction checkers indicate that no specific drug interactions have been formally found between Cetirizine Hydrochloride and common hormonal contraceptives. The information is consistent across health authority data.


Q: What is the patent status of Xeniler?

The core active ingredient, Cetirizine Hydrochloride, is widely available in approved generic forms, meaning the initial patents covering the oral formulation have expired. Other patents may still be active for specific formulations, such as the IV solution or pediatric preparations.


Q: How quickly do people typically notice an effect after starting Xeniler?

Studies on the effect of Xeniler showed that activity typically begins very quickly. The onset of action after a single dose occurred within 20 minutes in half of the subjects studied and within one hour in 95% of subjects.


Q: What is the typical time frame for Xeniler to reach its full effect?

The medicine is rapidly absorbed, with maximum concentration in the blood reached in about one hour. The effects are typically sustained for at least 24 hours, and the medicine is approved for once daily use.


Q: Are there any common over-the-counter medicines that should be avoided with Xeniler?

Official interaction statements advise caution with other oral antihistamines and many nighttime cold medications. This is because combining these products can lead to increased drowsiness or other additive depressant effects on the central nervous system.


Q: Has Xeniler been approved for use in children?

Yes, Xeniler is approved for use in the pediatric population. The official labeling specifies approval for children aged 6 months and older (via oral solution or IV formulation), with the tablet generally recommended for children six years and older.


Q: What happens if Xeniler is stopped suddenly?

Official regulatory updates note that stopping the medicine suddenly after long-term daily use (typically a few months or more) may result in a rare side effect of severe, widespread itching, known as pruritus.


Q: Is there any research on Xeniler and driving ability?

Official labeling includes a warning that drowsiness may occur as an adverse reaction. Therefore, individuals should exercise caution when driving a motor vehicle or operating machinery until they know how the medicine affects them.


Q: Is it true that Xeniler has an interaction with grapefruit juice?

The official product information notes that taking the medicine with food can slow the rate of its absorption, though the total amount absorbed remains the same. Specific warnings regarding a clinical interaction with grapefruit juice are not typically listed in the core regulatory drug information.


Q: How long does Xeniler stay in your system after stopping it?

The mean elimination half-life is approximately 11 hours in adults with normal kidney function. Based on this clearance rate, the substance is generally understood to be cleared from the bloodstream within the day following the final dose.


Q: How are the benefits and risks of Xeniler generally balanced?

The medicine was approved based on a regulatory assessment which found that the symptomatic benefits for allergic manifestations generally outweigh the officially documented risks. The regulatory approval is based on its use according to established contraindications, warnings, and dosage adjustments.


Q: Is there a link between Xeniler and changes in mood?

Official adverse event lists include agitation as an uncommon reaction. However, more significant mental status changes, such as pronounced changes in mood or irrational behavior, have primarily been reported as symptoms of overdose, not standard use.


Q: Does Xeniler contain gluten or lactose?

Official information regarding inactive ingredients shows that some oral tablet formulations do list lactose monohydrate as an ingredient. The regulatory labeling also states that the product contains no ingredient made from a gluten-containing grain.


Q: Can Xeniler cause dry mouth or constipation?

Dry mouth is officially documented as a common adverse reaction, affecting up to 1 in 10 people. However, constipation is not listed among the most frequent (common, uncommon, rare, or very rare) gastrointestinal adverse events in the regulatory safety profile.

How should Xeniler be stored and disposed of?

The official storage and disposal requirements for Xeniler (Cetirizine Hydrochloride) are mandated by regulatory agencies to ensure stability and safety.

Storage Conditions

Xeniler must be stored at Controlled Room Temperature (CRT), maintaining a range between 20 C to 25 C (68 F to 77 F). The product must be stored in its original container, and the oral solution cap should be tightly closed after each use. The medicine must always be kept out of the reach of children.

Disposal Instructions

Unused or expired Xeniler should be discarded in accordance with local regulations. The FDA recommends using authorized drug take-back programs where available. If no take-back program is accessible, the medicine should be prepared for household trash disposal following official guidelines, avoiding flushing unless explicitly instructed by the product labeling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Xeniler found in:

A-Z Index: